Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials for the Combination of ZG006 for Injection with PD-1/PD-L1 Immune Checkpoint Inhibitor

· Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange

On 6ix: 6ix.com/news/announcement-on-voluntary-disclosure-of-obtaining-notice-of-approval-for-drug-clinical-trials-for-the-combination-of-zg006-for-injection-with-pd-1pd-l1-immune-checkpoint-inhibitor

Announcement on Voluntary Disclosure of Obtaining Notice of Approval for Drug Clinical Trials for the Combination of ZG006 for Injection with PD-1/PD-L1 Immune Checkpoint Inhibitor

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis